Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas Report on Five Patients and a Review of the Literature

Frédéric Amant; An Coosemans; Vincent Renard; Els Everaert; Ignace Vergote

doi:https://doi.org/10.1111/IGC.0b013e31819c0f59

Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas Report on Five Patients and a Review of the Literature

Frédéric Amant, An Coosemans, Vincent Renard, Els Everaert, Ignace Vergote

Other Departments

Research output: Contribution to journal › Review article › Academic › peer-review

24 Citations (Scopus)

Abstract

The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and Undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in 2/5 patients, of which I had a partial remission during 9 months. Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated. When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of I I patients with a clinical benefit in 7 (64%) of I I patients. These results on the Use of ET-743 in uterine sarcoma patients support the conductance of larger trials

Original language	English
Pages (from-to)	245-248
Journal	International journal of gynecological cancer
Volume	19
Issue number	2
DOIs	https://doi.org/10.1111/IGC.0b013e31819c0f59
Publication status	Published - 2009

Access to Document

https://doi.org/10.1111/IGC.0b013e31819c0f59

Cite this

@article{617dbf136419488796698068999887d3,

title = "Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas Report on Five Patients and a Review of the Literature",

abstract = "The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and Undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in 2/5 patients, of which I had a partial remission during 9 months. Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated. When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of I I patients with a clinical benefit in 7 (64%) of I I patients. These results on the Use of ET-743 in uterine sarcoma patients support the conductance of larger trials",

author = "Fr{\'e}d{\'e}ric Amant and An Coosemans and Vincent Renard and Els Everaert and Ignace Vergote",

year = "2009",

doi = "https://doi.org/10.1111/IGC.0b013e31819c0f59",

language = "English",

volume = "19",

pages = "245--248",

journal = "International journal of gynecological cancer",

issn = "1048-891X",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas Report on Five Patients and a Review of the Literature

AU - Amant, Frédéric

AU - Coosemans, An

AU - Renard, Vincent

AU - Everaert, Els

AU - Vergote, Ignace

PY - 2009

Y1 - 2009

N2 - The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and Undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in 2/5 patients, of which I had a partial remission during 9 months. Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated. When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of I I patients with a clinical benefit in 7 (64%) of I I patients. These results on the Use of ET-743 in uterine sarcoma patients support the conductance of larger trials

AB - The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and Undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated. Current data show a clinical benefit in 2/5 patients, of which I had a partial remission during 9 months. Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated. When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of I I patients with a clinical benefit in 7 (64%) of I I patients. These results on the Use of ET-743 in uterine sarcoma patients support the conductance of larger trials

U2 - https://doi.org/10.1111/IGC.0b013e31819c0f59

DO - https://doi.org/10.1111/IGC.0b013e31819c0f59

M3 - Review article

C2 - 19396002

SN - 1048-891X

VL - 19

SP - 245

EP - 248

JO - International journal of gynecological cancer

JF - International journal of gynecological cancer

IS - 2

ER -